FDA approves first non-surgical treatment for 2 rare cancers

The Food and Drug Administration on Tuesday approved the first ever non-surgical treatment for the rare neuroendocrine cancers: pheochromocytoma and paraganglioma. The approval for Azedra, a drug developed by Progenics Pharmacecuticals of Tarrytown, N.Y., was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. “This is a true breakthrough," said Dr. Daniel A. Pryma, an associate professor of radiology and radiation…

http://feeds.bizjournals.com/~r/industry_6/~3/BlYPPlheZ_U/fda-okays-non-surgical...

Source: bizjournals.com Health Care:Physician Practices headlines - July 31, 2018 Category: American Health Authors: John George Source Type: news